Indrayani Biotech opened lower at ₹8.00, compared with its previous close of ₹8.16. In the last trading session on 12 Nov 2026, the stock traded between ₹8.00 and ₹8.56, with an average traded price of ₹8.50. It showed an upward intraday trend.
An investment of ₹10,000 made 5 years ago in Indrayani Biotech is now worth
₹ 2,953.00
Resulting in a loss of
₹ 7,047.00 (70.47%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
+0.40 (+4.90%)
Day High
₹8.56
Day Low
₹8.00
Day Open
₹8.00
Prev Close
₹8.16
Volume
27,088
Value Traded
₹0.02 Cr
1W Return
7.00%
1M Return
-6.35%
3M Return
8.49%
6M Return
-23.64%
1Y Return
-48.99%
Market Cap (₹ Cr.)
67
PE Ratio
24.70
PB Ratio
0.52
Dividend Yield
-
ROE
-6.11%
ROCE
3.64%
Book Value (₹)
15.59
Face Value (₹)
10.00
EPS (TTM)
0.06
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
7.00%
6 Weeks
-
1 Month
-6.35%
3 Months
8.49%
9 Months
-11.11%
Indrayani Biotech sets 34th AGM for Nov 30 at 3 pm; approves RPTs
Indrayani Biotech scheduled its 34th AGM for November 30, 2026, at 3:00 pm via VC/OAVM. Board approved related party transactions up to ₹25 crore with six subsidiaries. Book closure period fixed from November 24 to November 30, 2026. Remote e-voting window opens on November 27, 2026, and closes on November 29, 2026.
6 days agoIndrayani Biotech gets BSE listing approval for 83.64 lakh rights shares
BSE granted listing approval for 83,64,036 equity shares on November 6, 2026. Shares are partly paid-up with a paid-up value of ₹3.75 each. Trading permission is subject to depository credit confirmation. Company's paid-up capital rose to ₹53.04 crore after allotment.
6 days agoIndrayani Biotech CS resigns on health grounds; new auditor named
C.S. Shanmuga Sundar resigned as Company Secretary and Compliance Officer effective November 2, 2026. Resignation attributed to personal health reasons requiring rest and avoidance of travel. Board appointed Ms. Nattery Srinivasan Poornima as Secretarial Auditor for FY26. Appointment fills casual vacancy left by previous auditor K. Ravichandran.
10 days agoIndrayani Biotech submits response to Income Tax recovery proceedings
Filed response to Income Tax Department regarding recovery letters for AY 2011-14. AY 2013-14 demand of ₹98,09,000 challenged as ITAT had set aside the original order. Combined demand of ₹18,45,520 for AY 2011-12 and 2012-13 under appeal since April 2022. Company asserts no immediate financial impact due to pending legal remedies.
22 days agoIndrayani Biotech Q1FY27 Results: Standalone PAT up 13.5% YoY
Standalone net profit rose 13.5% YoY to ₹14.50 lakh in Q1FY27. Consolidated net profit surged to ₹54.00 lakh from ₹15.65 lakh in Q1FY26. Standalone revenue fell 37.9% YoY to ₹415.34 lakh. Consolidated revenue grew 29.6% YoY to ₹3,770.55 lakh.
1mo agoIndrayani Biotech sells 1.83% stake in subsidiary Dindigul Farm
Indrayani Biotech sold 1.83% stake in subsidiary Dindigul Farm Product Limited. Sale completed via open market on September 30, 2026. Post-disposal holding stands at 27.05%. Subsidiary contributed 65.33% to revenues in last financial year.
1mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹904.25 | +0.25% | ₹1,17,569.54 | 56.60 | +25.42% | |
| ₹1,084.00 | -0.12% | ₹1,07,282.96 | 62.90 | -6.71% | |
| ₹424.00 | -1.58% | ₹46,135.80 | 23.80 | -27.93% | |
| ₹165.21 | -1.77% | ₹21,471.99 | 19.00 | -39.46% | |
| ₹428.35 | -0.84% | ₹14,874.58 | 22.80 | +2.92% | |
| ₹665.05 | +2.20% | ₹14,072.29 | 32.70 | +48.07% | |
| ₹983.50 | -0.57% | ₹13,132.47 | 28.60 | -7.33% | |
| ₹440.00 | +4.61% | ₹10,071.16 | 11.40 | +12.92% | |
| ₹148.28 | -0.47% | ₹6,801.17 | 13.40 | +38.49% | |
| ₹227.74 | -0.21% | ₹6,720.30 | 14.50 | +23.97% | |
| ₹252.79 | +1.85% | ₹5,570.56 | 16.00 | +10.80% | |
| ₹558.95 | -5.66% | ₹5,509.69 | 41.50 | -12.60% |
An investment of ₹10,000 made 5 years ago in Indrayani Biotech is now worth
₹ 2,953.00
Resulting in a loss of
₹ 7,047.00 (70.47%)
Note: Past profits do not guarantee future returns.
